R to @EMA_News: In 2023, we approved 8 #biosimilars for a wide range of diseases, including a rare genetic disease, #cancers, #multiplesclerosis.

The total of 9⃣7⃣ biosimilars that can be marketed in 🇪🇺 make treatments more accessible and can improve the quality of life for more #patients.

🐦🔗: https://nitter.cz/EMA_News/status/1747252697924006358#m

[2024-01-16 13:41 UTC]